Kinnate Biopharma Inc. to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
Kinnate Biopharma Inc. (Nasdaq: KNTE) announced that CEO Nima Farzan will participate in the 'Bullseye - Targeted Oncology - Quanta of Targets' panel at the Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022, at 10:20 a.m. ET. The Kinnate management team will also conduct investor meetings during the event. A live webcast will be available in the 'Investors and Media' section on the company's website, with a replay accessible for 30 days post-event. Kinnate focuses on developing targeted therapies for oncogenic drivers in cancer patients.
- None.
- None.
SAN FRANCISCO and SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief executive officer, Nima Farzan, will participate in the “Bullseye - Targeted Oncology - Quanta of Targets” panel at the Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022 at 10:20 a.m. ET.
Members of the Kinnate management team will also host investor meetings during the conference.
Investors and the general public are invited to listen to a live webcast of the session through the "Investors and Media" section on Kinnate.com. A webcast replay will be made available following the event for 30 days.
About Kinnate Biopharma Inc.
Kinnate Biopharma Inc. is a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer. The company is developing medicines for known oncogenic drivers where there are no approved targeted drugs and to overcome the limitations of marketed cancer therapies, such non-responsiveness or acquired and intrinsic resistance. Kinnate has two lead clinical programs being studied in solid tumors with RAF, NRAS and FGFR-driven alterations, and is rapidly progressing a pipeline of additional small molecule drug candidates as part of the Kinnate Discovery Engine. The company is driven by the urgency and knowledge that patients are waiting for new, effective cancer medicines. For more information, visit Kinnate.com and follow us on LinkedIn.
Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are also intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends. Such expectations and projections may never materialize or may prove to be incorrect. These forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors as described under the heading “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022 that we have filed with the Securities and Exchange Commission (the “SEC”), as well as in our subsequent filings we make with the SEC. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. Investors should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Our forward-looking statements speak only as of the date of this release, and except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason in the future.
Investor & Media Contact:
Priyanka Shah | Priyanka.Shah@kinnate.com | +1-908-447-6134
FAQ
What is the date and time of the Kinnate Biopharma conference participation?
Where can I listen to the Kinnate Biopharma conference webcast?
What is the focus of Kinnate Biopharma's research?
Who is participating in the panel for Kinnate Biopharma?
How long will the Kinnate Biopharma conference replay be available?
